AI, XDCs, small nucleic acids, macrocyclic peptide, in vivo CAR‑T and radiopharmaceuticals are reshaping the global landscape of novel drug R&D. Seven years after its STAR Market listing, Medicilon keeps pace with this paradigm shift. We proactively build service platforms ahead of market needs and industry changes, developing a diversified preclinical service ecosystem spanning from target identification to IND filing.
01 MAIDD: AI Drug Discovery Platform
AI has become a foundational engine for drug discovery. Medicilon’s MAIDD platform unifies platforms for small molecules, small nucleic acids, macrocyclic peptide and peptides. It delivers core capabilities including protein structure prediction, intelligent molecular design and AI‑ADMET profiling, forming a closed “computational prediction + experimental validation” wet-dry workflow. The platform accelerates molecular optimization for PROTACs, XDCs and small nucleic acids across target identification and lead candidate screening, shortening R&D cycles via algorithmic intelligence.
02 NAMs Platform
Medicilon’s NAMs platform adopts a tripartite framework combining human cell models, AI prediction and organoids. Integrating organoids, organ-on-a-chip systems and PBPK modelling to complement traditional GLP animal studies, it generates reliable data for IND applications. These alternative models cut costs and boost efficiency while opening new avenues for preclinical safety assessment.
03 XDC Platform
The conjugate drug has expanded beyond classic ADCs toward multi-payload, multi-target and multi-modal XDCs. Medicilon’s XDC platform supports ADCs, PDCs, APCs and other conjugate formats, covering payload synthesis, conjugation process development, pharmacodynamic, PK and safety evaluation. Drawing on extensive project experience, we have supported 36 ADC programs to enter clinical development, including 6 with overseas licensing deals.
As antibody‑oligonucleotide conjugates, AOCs merge antibody targeting and nucleic acid therapeutics to address key delivery bottlenecks for small nucleic acids. Leveraging our MOD design platform for target sequence engineering and a library of over 80 nucleotide modification monomers, we offer custom synthesis, conjugation and characterization from milligram to gram scale. The platform delivers end-to-end target-to-IND services to solve small nucleic acid delivery challenges.
04 Peptide & Macrocyclic peptide Platform
Peptide therapeutics are evolving toward highly selective and stable macrocyclic peptide formats. Centered on mRNA display technology, Medicilon has built peptide and macrocyclic peptide libraries with diversity exceeding 10¹³. Our technical toolkit includes solid‑ and solution-phase synthesis, non-canonical amino acid incorporation and DBX cyclization. The full workflow covers target validation, lead discovery, cyclization optimization, in vitro/in vivo pharmacology, PK/PD and safety assessment, enabling development of these traditionally hard-to-drug molecules.
Medicilon also offers one-stop preclinical support for GLP‑1 programs, spanning discovery, pharmaceutical development, pharmacodynamics, PK and safety evaluation. To date, we have helped 22 GLP‑1 candidates enter clinical trials, with 7 licensed out to partners.
05 Nucleic Acid Platform
Nucleic Acid remain one of the fastest growing therapeutic classes. Medicilon’s integrated platform covers discovery, chemical modification, CMC, formulation delivery, bioanalysis, pharmacology and PK/PD evaluation for siRNA, AOC and other oligonucleotide assets.
We maintain a broad library of modified building blocks and in-house expertise in GalNAc and LNP delivery systems. Specialized in vivo models including cynomolgus monkey liver puncture and intrathecal injection are available. The platform also supports preclinical development of mRNA vaccines, including sequence and delivery optimization, quality control, pharmacology and GLP safety studies.
06 TPD Platform
Targeted protein degradation (TPD) unlocks previously undruggable targets. Medicilon’s TPD platform maintains libraries of E3 ligase ligands and PROTAC linkers for PROTACs and molecular glues. We rapidly synthesize potent degrader molecules, paired with full in vitro/in vivo pharmacology, PK and safety packages. As of September 2026, 8 PROTAC programs advanced into clinical studies with our support, bringing viable solutions for undruggable targets.
07 CGT Platform
Cell and gene therapy (CGT) represents a cutting-edge frontier in life sciences. Medicilon’s CGT platform supports major modalities including CAR‑T, TCR‑T, CAR‑NK and TIL, providing end-to-end preclinical services for pharmacology, PK, bioanalysis and safety assessment. As of June 2026, 9 cell therapy candidates have moved into clinical trials with our support.
We have built a dedicated platform for transformational in vivo CAR‑T programs, covering ex vivo production, in vivo pharmacology, biodistribution, immunogenicity, immune toxicity and genomic integration risk assessment. Multiple programs have completed preclinical work and progressed toward filing.
08 Radiopharmaceutical Platform
For radiopharmaceuticals, Medicilon has established a dedicated preclinical evaluation system. We leverage SPECT and PET imaging for quantitative analysis of radiopharmaceuticals, paired with oncology animal models for pharmacology and safety testing, filling gaps in preclinical evaluation for radioactive therapeutics.
09 Antibody Platform
Medicilon’s antibody platform supports mAbs, BsAbs and MsAbs across drug discovery, CMC, GLP pharmacodynamics, PK and safety assessment. Continuous upgrades in BsAbs, MsAbs and antibody conjugates create synergies with our new modality platforms. As of June 2026, Medicilon has supported 51 antibody candidates into clinical development.
New technologies and R&D paradigms keep emerging, yet Medicilon stays committed to continuous exploration.
Moving forward, Medicilon will keep abreast of next-generation therapeutics, refining and upgrading all technical platforms to overcome hurdles for complex molecules and novel modalities. With our integrated preclinical platform, we stand ready to help global biotech innovators advance more drug candidates from target identification to IND submission.